Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Common Equity: 2019-2024

Historic Common Equity for Benitec Biopharma (BNTC) over the last 6 years, with Jun 2024 value amounting to $47.2 million.

  • Benitec Biopharma's Common Equity rose 2662.22% to $317.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $317.7 million, marking a year-over-year increase of 2662.22%. This contributed to the annual value of $47.2 million for FY2024, which is 23290.10% up from last year.
  • As of FY2024, Benitec Biopharma's Common Equity stood at $47.2 million, which was up 23,290.10% from $202,000 recorded in FY2023.
  • Over the past 5 years, Benitec Biopharma's Common Equity peaked at $47.2 million during FY2024, and registered a low of $202,000 during FY2023.
  • For the 3-year period, Benitec Biopharma's Common Equity averaged around $16.8 million, with its median value being $2.9 million (2022).
  • Per our database at Business Quant, Benitec Biopharma's Common Equity tumbled by 92.99% in 2023 and then soared by 23,290.10% in 2024.
  • Over the past 5 years, Benitec Biopharma's Common Equity (Yearly) stood at $10.2 million in 2020, then spiked by 95.45% to $20.0 million in 2021, then crashed by 85.60% to $2.9 million in 2022, then slumped by 92.99% to $202,000 in 2023, then spiked by 23,290.10% to $47.2 million in 2024.